Susan A Berry1, Nicola Longo2, George A Diaz3, Shawn E McCandless4, Wendy E Smith5, Cary O Harding6, Roberto Zori7, Can Ficicioglu8, Uta Lichter-Konecki9, Beth Robinson10, Jerry Vockley11. 1. University of Minnesota, Minneapolis, MN, USA. 2. University of Utah, Salt Lake City, UT, USA. 3. Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Center for Human Genetics, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA. 5. Maine Medical Center, Portland, ME, USA. 6. Oregon Health & Science University, Portland, OR, USA. 7. University of Florida, Gainesville, FL, USA. 8. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 9. Children's Hospital of Pittsburgh, Pittsburgh, PA, USA. 10. Horizon Pharma USA, Inc., Lake Forest, IL, USA. Electronic address: brobinson@horizonpharma.com. 11. Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
INTRODUCTION: Glycerol phenylbutyrate (GPB) is approved in the US for the management of patients 2months of age and older with urea cycle disorders (UCDs) that cannot be managed with protein restriction and/or amino acid supplementation alone. Limited data exist on the use of nitrogen conjugation agents in very young patients. METHODS: Seventeen patients (15 previously on other nitrogen scavengers) with all types of UCDs aged 2months to 2years were switched to, or started, GPB. Retrospective data up to 12months pre-switch and prospective data during initiation of therapy were used as baseline measures. The primary efficacy endpoint of the integrated analysis was the successful transition to GPB with controlled ammonia (<100μmol/L and no clinical symptoms). Secondary endpoints included glutamine and levels of other amino acids. Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development. RESULTS: 82% and 53% of patients completed 3 and 6months of therapy, respectively (mean 8.85months, range 6days-18.4months). Patients transitioned to GPB maintained excellent control of ammonia and glutamine levels. There were 36 HACs in 11 patients before GPB and 11 in 7 patients while on GPB, with a reduction from 2.98 to 0.88 episodes per year. Adverse events occurring in at least 10% of patients while on GPB were neutropenia, vomiting, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash/papule. CONCLUSION: GPB was safe and effective in UCD patients aged 2months to 2years. GPB use was associated with good short- and long-term control of ammonia and glutamine levels, and the annualized frequency of hyperammonemic crises was lower during the study than before the study. There was no evidence for any previously unknown toxicity of GPB.
INTRODUCTION:Glycerol phenylbutyrate (GPB) is approved in the US for the management of patients 2months of age and older with urea cycle disorders (UCDs) that cannot be managed with protein restriction and/or amino acid supplementation alone. Limited data exist on the use of nitrogen conjugation agents in very young patients. METHODS: Seventeen patients (15 previously on other nitrogen scavengers) with all types of UCDs aged 2months to 2years were switched to, or started, GPB. Retrospective data up to 12months pre-switch and prospective data during initiation of therapy were used as baseline measures. The primary efficacy endpoint of the integrated analysis was the successful transition to GPB with controlled ammonia (<100μmol/L and no clinical symptoms). Secondary endpoints included glutamine and levels of other amino acids. Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development. RESULTS: 82% and 53% of patients completed 3 and 6months of therapy, respectively (mean 8.85months, range 6days-18.4months). Patients transitioned to GPB maintained excellent control of ammonia and glutamine levels. There were 36 HACs in 11 patients before GPB and 11 in 7 patients while on GPB, with a reduction from 2.98 to 0.88 episodes per year. Adverse events occurring in at least 10% of patients while on GPB were neutropenia, vomiting, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash/papule. CONCLUSION:GPB was safe and effective in UCD patients aged 2months to 2years. GPB use was associated with good short- and long-term control of ammonia and glutamine levels, and the annualized frequency of hyperammonemic crises was lower during the study than before the study. There was no evidence for any previously unknown toxicity of GPB.
Authors: Roland Posset; Andrea L Gropman; Sandesh C S Nagamani; Lindsay C Burrage; Jirair K Bedoyan; Derek Wong; Gerard T Berry; Matthias R Baumgartner; Marc Yudkoff; Matthias Zielonka; Georg F Hoffmann; Peter Burgard; Andreas Schulze; Shawn E McCandless; Angeles Garcia-Cazorla; Jennifer Seminara; Sven F Garbade; Stefan Kölker Journal: Ann Neurol Date: 2019-05-13 Impact factor: 10.422
Authors: Xia Mao; Helen Chen; Allen Z Lin; Sun Kim; Michael E Burczynski; Erqian Na; Gabor Halasz; Mark W Sleeman; Andrew J Murphy; Haruka Okamoto; Xiping Cheng Journal: J Inherit Metab Dis Date: 2022-02-04 Impact factor: 4.750
Authors: Elena Martín-Hernández; Pilar Quijada-Fraile; Patricia Correcher; Silvia Meavilla; Paula Sánchez-Pintos; Javier de Las Heras Montero; Javier Blasco-Alonso; Lucy Dougherty; Ana Marquez; Luis Peña-Quintana; Elvira Cañedo; María Concepción García-Jimenez; Pedro Juan Moreno Lozano; Mercedes Murray Hurtado; María Camprodon Gómez; Delia Barrio-Carreras; Mariela de Los Santos; Mireia Del Toro; María L Couce; Isidro Vitoria Miñana; Montserrat Morales Conejo; Marcello Bellusci Journal: J Clin Med Date: 2022-08-28 Impact factor: 4.964